Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Arm, Multicenter Phase IIIB Clinical Trial to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

Trial Profile

A Single-Arm, Multicenter Phase IIIB Clinical Trial to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2018

At a glance

  • Drugs Emicizumab (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Registrational
  • Acronyms STASEY
  • Sponsors Roche
  • Most Recent Events

    • 07 Dec 2018 Status changed from recruiting to active, no longer recruiting.
    • 24 Apr 2018 This trial has been Discontinued in Denmark.
    • 14 Sep 2017 Planned End Date changed from 12 Aug 2020 to 4 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top